APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oncology (Anti-cancer Drugs)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oncology (Anti-cancer Drugs) Market Outlook and Growth Opportunities 2026

Report ID 174018900421 December 2025195 pages

Choose your research edition.

Industry ResearchOncology (Anti-cancer Drugs) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology (Anti-cancer Drugs) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Oncology (Anti-cancer Drugs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology (Anti-cancer Drugs) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology (Anti-cancer Drugs) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Oncology (Anti-cancer Drugs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oncology (Anti-cancer Drugs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncology (Anti-cancer Drugs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncology (Anti-cancer Drugs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oncology (Anti-cancer Drugs) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oncology (Anti-cancer Drugs) market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli lilly, Pfizer, GlaxoSmithKline and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oncology (Anti-cancer Drugs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncology (Anti-cancer Drugs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncology (Anti-cancer Drugs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oncology (Anti-cancer Drugs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Oncology (Anti-cancer Drugs) Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli lilly

Pfizer

GlaxoSmithKline

Amgen

Celgene

Oncology (Anti-cancer Drugs) Segment by Type

Blood Cancer

Gastrointestinal Cancer

Breast Cancer

Prostate Cancer

Others

Oncology (Anti-cancer Drugs) Segment by Application

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Chemotherapy

Targeted Therapy

Others

Oncology (Anti-cancer Drugs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncology (Anti-cancer Drugs) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Oncology (Anti-cancer Drugs) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncology (Anti-cancer Drugs) significant trends, drivers, influence factors in global and regions.

6. To analyze Oncology (Anti-cancer Drugs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology (Anti-cancer Drugs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology (Anti-cancer Drugs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology (Anti-cancer Drugs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oncology (Anti-cancer Drugs) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncology (Anti-cancer Drugs) industry.

Chapter 3: Detailed analysis of Oncology (Anti-cancer Drugs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Oncology (Anti-cancer Drugs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Oncology (Anti-cancer Drugs) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncology (Anti-cancer Drugs) Industry Trends Table 2. Oncology (Anti-cancer Drugs) Industry Drivers Table 3. Oncology (Anti-cancer Drugs) Industry Opportunities and Challenges Table 4. Oncology (Anti-cancer Drugs) Industry Restraints Table 5. Global Oncology (Anti-cancer Drugs) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncology (Anti-cancer Drugs) Revenue Share by Company (2021-2026) Table 7. Global Oncology (Anti-cancer Drugs) Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Oncology (Anti-cancer Drugs) Sales Volume Share by Company (2021-2026) Table 9. Global Oncology (Anti-cancer Drugs) Average Price (US$/ton) of Company (2021-2026) Table 10. Global Oncology (Anti-cancer Drugs) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Oncology (Anti-cancer Drugs) Key Company Manufacturing Base & Headquarters Table 12. Global Oncology (Anti-cancer Drugs) Company, Product Type & Application Table 13. Global Oncology (Anti-cancer Drugs) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Oncology (Anti-cancer Drugs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Blood Cancer Table 18. Significant Companies of Gastrointestinal Cancer Table 19. Significant Companies of Breast Cancer Table 20. Significant Companies of Prostate Cancer Table 21. Significant Companies of Others Table 22. Global Oncology (Anti-cancer Drugs) Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 23. Global Oncology (Anti-cancer Drugs) Sales Volume by Type (2021-2026) & (k tons) Table 24. Global Oncology (Anti-cancer Drugs) Sales Volume by Type (2027-2032) & (k tons) Table 25. Global Oncology (Anti-cancer Drugs) Sales Volume Share by Type (2021-2026) Table 26. Global Oncology (Anti-cancer Drugs) Sales Volume Share by Type (2027-2032) Table 27. Global Oncology (Anti-cancer Drugs) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oncology (Anti-cancer Drugs) Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Oncology (Anti-cancer Drugs) Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Oncology (Anti-cancer Drugs) Sales Value Share by Type (2021-2026) Table 31. Global Oncology (Anti-cancer Drugs) Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Immunotherapy (Biologic Therapy) Table 33. Significant Companies of Hormonal Therapy Table 34. Significant Companies of Chemotherapy Table 35. Significant Companies of Targeted Therapy Table 36. Significant Companies of Others Table 37. Global Oncology (Anti-cancer Drugs) Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 38. Global Oncology (Anti-cancer Drugs) Sales Volume by Application (2021-2026) & (k tons) Table 39. Global Oncology (Anti-cancer Drugs) Sales Volume by Application (2027-2032) & (k tons) Table 40. Global Oncology (Anti-cancer Drugs) Sales Volume Share by Application (2021-2026) Table 41. Global Oncology (Anti-cancer Drugs) Sales Volume Share by Application (2027-2032) Table 42. Global Oncology (Anti-cancer Drugs) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Oncology (Anti-cancer Drugs) Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Oncology (Anti-cancer Drugs) Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Oncology (Anti-cancer Drugs) Sales Value Share by Application (2021-2026) Table 46. Global Oncology (Anti-cancer Drugs) Sales Value Share by Application (2027-2032) Table 47. Global Oncology (Anti-cancer Drugs) Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 48. Global Oncology (Anti-cancer Drugs) Sales by Region (2021-2026) & (k tons) Table 49. Global Oncology (Anti-cancer Drugs) Sales Market Share by Region (2021-2026) Table 50. Global Oncology (Anti-cancer Drugs) Sales by Region (2027-2032) & (k tons) Table 51. Global Oncology (Anti-cancer Drugs) Sales Market Share by Region (2027-2032) Table 52. Global Oncology (Anti-cancer Drugs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Oncology (Anti-cancer Drugs) Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Oncology (Anti-cancer Drugs) Sales Value Share by Region (2021-2026) Table 55. Global Oncology (Anti-cancer Drugs) Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Oncology (Anti-cancer Drugs) Sales Value Share by Region (2027-2032) Table 57. Global Oncology (Anti-cancer Drugs) Market Average Price (US$/ton) by Region (2021-2026) Table 58. Global Oncology (Anti-cancer Drugs) Market Average Price (US$/ton) by Region (2027-2032) Table 59. Global Oncology (Anti-cancer Drugs) Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 60. Global Oncology (Anti-cancer Drugs) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Oncology (Anti-cancer Drugs) Sales by Country (2021-2026) & (k tons) Table 62. Global Oncology (Anti-cancer Drugs) Sales Market Share by Country (2021-2026) Table 63. Global Oncology (Anti-cancer Drugs) Sales by Country (2027-2032) & (k tons) Table 64. Global Oncology (Anti-cancer Drugs) Sales Market Share by Country (2027-2032) Table 65. Global Oncology (Anti-cancer Drugs) Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Oncology (Anti-cancer Drugs) Sales Value Market Share by Country (2021-2026) Table 67. Global Oncology (Anti-cancer Drugs) Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Oncology (Anti-cancer Drugs) Sales Value Market Share by Country (2027-2032) Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Sanofi Oncology (Anti-cancer Drugs) Product Portfolio Table 73. Sanofi Recent Development Table 74. Johnson & Johnson Company Information Table 75. Johnson & Johnson Business Overview Table 76. Johnson & Johnson Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Johnson & Johnson Oncology (Anti-cancer Drugs) Product Portfolio Table 78. Johnson & Johnson Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Novartis Oncology (Anti-cancer Drugs) Product Portfolio Table 83. Novartis Recent Development Table 84. Merck Company Information Table 85. Merck Business Overview Table 86. Merck Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. Merck Oncology (Anti-cancer Drugs) Product Portfolio Table 88. Merck Recent Development Table 89. Roche Company Information Table 90. Roche Business Overview Table 91. Roche Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Roche Oncology (Anti-cancer Drugs) Product Portfolio Table 93. Roche Recent Development Table 94. Eli lilly Company Information Table 95. Eli lilly Business Overview Table 96. Eli lilly Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Eli lilly Oncology (Anti-cancer Drugs) Product Portfolio Table 98. Eli lilly Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Pfizer Oncology (Anti-cancer Drugs) Product Portfolio Table 103. Pfizer Recent Development Table 104. GlaxoSmithKline Company Information Table 105. GlaxoSmithKline Business Overview Table 106. GlaxoSmithKline Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. GlaxoSmithKline Oncology (Anti-cancer Drugs) Product Portfolio Table 108. GlaxoSmithKline Recent Development Table 109. Amgen Company Information Table 110. Amgen Business Overview Table 111. Amgen Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 112. Amgen Oncology (Anti-cancer Drugs) Product Portfolio Table 113. Amgen Recent Development Table 114. Celgene Company Information Table 115. Celgene Business Overview Table 116. Celgene Oncology (Anti-cancer Drugs) Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 117. Celgene Oncology (Anti-cancer Drugs) Product Portfolio Table 118. Celgene Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. Oncology (Anti-cancer Drugs) Distributors List Table 122. Oncology (Anti-cancer Drugs) Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Oncology (Anti-cancer Drugs) Product Image Figure 2. Global Oncology (Anti-cancer Drugs) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology (Anti-cancer Drugs) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Oncology (Anti-cancer Drugs) Sales (2021-2032) & (k tons) Figure 5. Global Oncology (Anti-cancer Drugs) Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Oncology (Anti-cancer Drugs) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Blood Cancer Image Figure 10. Gastrointestinal Cancer Image Figure 11. Breast Cancer Image Figure 12. Prostate Cancer Image Figure 13. Others Image Figure 14. Global Oncology (Anti-cancer Drugs) Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 15. Global Oncology (Anti-cancer Drugs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Oncology (Anti-cancer Drugs) Sales Volume Share by Type (2021-2032) Figure 17. Global Oncology (Anti-cancer Drugs) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Oncology (Anti-cancer Drugs) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Oncology (Anti-cancer Drugs) Sales Value Share by Type (2021-2032) Figure 20. Immunotherapy (Biologic Therapy) Image Figure 21. Hormonal Therapy Image Figure 22. Chemotherapy Image Figure 23. Targeted Therapy Image Figure 24. Others Image Figure 25. Global Oncology (Anti-cancer Drugs) Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 26. Global Oncology (Anti-cancer Drugs) Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Oncology (Anti-cancer Drugs) Sales Volume Share by Application (2021-2032) Figure 28. Global Oncology (Anti-cancer Drugs) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Oncology (Anti-cancer Drugs) Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Oncology (Anti-cancer Drugs) Sales Value Share by Application (2021-2032) Figure 31. Global Oncology (Anti-cancer Drugs) Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 32. Global Oncology (Anti-cancer Drugs) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Oncology (Anti-cancer Drugs) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Oncology (Anti-cancer Drugs) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Oncology (Anti-cancer Drugs) Sales Value (2021-2032) & (US$ Million) Figure 36. North America Oncology (Anti-cancer Drugs) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Oncology (Anti-cancer Drugs) Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Oncology (Anti-cancer Drugs) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Oncology (Anti-cancer Drugs) Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Oncology (Anti-cancer Drugs) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Oncology (Anti-cancer Drugs) Sales Value (2021-2032) & (US$ Million) Figure 42. South America Oncology (Anti-cancer Drugs) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Oncology (Anti-cancer Drugs) Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Oncology (Anti-cancer Drugs) Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Oncology (Anti-cancer Drugs) Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Oncology (Anti-cancer Drugs) Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Cancer
  • Gastrointestinal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others
Applications
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Chemotherapy
  • Targeted Therapy
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli lilly
  • Pfizer
  • GlaxoSmithKline
  • Amgen
  • Celgene

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Oncology (Anti-cancer Drugs) Sales Value (2021-2032)
  4. 1.2.2 Global Oncology (Anti-cancer Drugs) Sales Volume (2021-2032)
  5. 1.2.3 Global Oncology (Anti-cancer Drugs) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Oncology (Anti-cancer Drugs) Market Dynamics
  1. 2.1 Oncology (Anti-cancer Drugs) Industry Trends
  2. 2.2 Oncology (Anti-cancer Drugs) Industry Drivers
  3. 2.3 Oncology (Anti-cancer Drugs) Industry Opportunities and Challenges
  4. 2.4 Oncology (Anti-cancer Drugs) Industry Restraints
3 Oncology (Anti-cancer Drugs) Market by Company
  1. 3.1 Global Oncology (Anti-cancer Drugs) Company Revenue Ranking in 2025
  2. 3.2 Global Oncology (Anti-cancer Drugs) Revenue by Company (2021-2026)
  3. 3.3 Global Oncology (Anti-cancer Drugs) Sales Volume by Company (2021-2026)
  4. 3.4 Global Oncology (Anti-cancer Drugs) Average Price by Company (2021-2026)
  5. 3.5 Global Oncology (Anti-cancer Drugs) Company Ranking (2024-2026)
  6. 3.6 Global Oncology (Anti-cancer Drugs) Company Manufacturing Base and Headquarters
  7. 3.7 Global Oncology (Anti-cancer Drugs) Company Product Type and Application
  8. 3.8 Global Oncology (Anti-cancer Drugs) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Oncology (Anti-cancer Drugs) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Oncology (Anti-cancer Drugs) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Oncology (Anti-cancer Drugs) Market by Type
  1. 4.1 Oncology (Anti-cancer Drugs) Type Introduction
  2. 4.1.1 Blood Cancer
  3. 4.1.2 Gastrointestinal Cancer
  4. 4.1.3 Breast Cancer
  5. 4.1.4 Prostate Cancer
  6. 4.1.5 Others
  7. 4.2 Global Oncology (Anti-cancer Drugs) Sales Volume by Type
  8. 4.2.1 Global Oncology (Anti-cancer Drugs) Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Oncology (Anti-cancer Drugs) Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Oncology (Anti-cancer Drugs) Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Oncology (Anti-cancer Drugs) Sales Value by Type
  12. 4.3.1 Global Oncology (Anti-cancer Drugs) Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Oncology (Anti-cancer Drugs) Sales Value by Type (2021-2032)
  14. 4.3.3 Global Oncology (Anti-cancer Drugs) Sales Value Share by Type (2021-2032)
5 Oncology (Anti-cancer Drugs) Market by Application
  1. 5.1 Oncology (Anti-cancer Drugs) Application Introduction
  2. 5.1.1 Immunotherapy (Biologic Therapy)
  3. 5.1.2 Hormonal Therapy
  4. 5.1.3 Chemotherapy
  5. 5.1.4 Targeted Therapy
  6. 5.1.5 Others
  7. 5.2 Global Oncology (Anti-cancer Drugs) Sales Volume by Application
  8. 5.2.1 Global Oncology (Anti-cancer Drugs) Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Oncology (Anti-cancer Drugs) Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Oncology (Anti-cancer Drugs) Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Oncology (Anti-cancer Drugs) Sales Value by Application
  12. 5.3.1 Global Oncology (Anti-cancer Drugs) Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Oncology (Anti-cancer Drugs) Sales Value by Application (2021-2032)
  14. 5.3.3 Global Oncology (Anti-cancer Drugs) Sales Value Share by Application (2021-2032)
6 Oncology (Anti-cancer Drugs) Regional Sales and Value Analysis
  1. 6.1 Global Oncology (Anti-cancer Drugs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncology (Anti-cancer Drugs) Sales by Region (2021-2032)
  3. 6.2.1 Global Oncology (Anti-cancer Drugs) Sales by Region: 2021-2026
  4. 6.2.2 Global Oncology (Anti-cancer Drugs) Sales by Region (2027-2032)
  5. 6.3 Global Oncology (Anti-cancer Drugs) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Oncology (Anti-cancer Drugs) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Oncology (Anti-cancer Drugs) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Oncology (Anti-cancer Drugs) Sales Value by Region (2027-2032)
  9. 6.5 Global Oncology (Anti-cancer Drugs) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Oncology (Anti-cancer Drugs) Sales Value (2021-2032)
  12. 6.6.2 North America Oncology (Anti-cancer Drugs) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Oncology (Anti-cancer Drugs) Sales Value (2021-2032)
  15. 6.7.2 Europe Oncology (Anti-cancer Drugs) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Oncology (Anti-cancer Drugs) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Oncology (Anti-cancer Drugs) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Oncology (Anti-cancer Drugs) Sales Value (2021-2032)
  21. 6.9.2 South America Oncology (Anti-cancer Drugs) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Oncology (Anti-cancer Drugs) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Oncology (Anti-cancer Drugs) Sales Value Share by Country, 2025 VS 2032
7 Oncology (Anti-cancer Drugs) Country-level Sales and Value Analysis
  1. 7.1 Global Oncology (Anti-cancer Drugs) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncology (Anti-cancer Drugs) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Oncology (Anti-cancer Drugs) Sales by Country (2021-2032)
  4. 7.3.1 Global Oncology (Anti-cancer Drugs) Sales by Country (2021-2026)
  5. 7.3.2 Global Oncology (Anti-cancer Drugs) Sales by Country (2027-2032)
  6. 7.4 Global Oncology (Anti-cancer Drugs) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Oncology (Anti-cancer Drugs) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Oncology (Anti-cancer Drugs) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Oncology (Anti-cancer Drugs) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Oncology (Anti-cancer Drugs) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Oncology (Anti-cancer Drugs) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Oncology (Anti-cancer Drugs) Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Oncology (Anti-cancer Drugs) Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Oncology (Anti-cancer Drugs) Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck Oncology (Anti-cancer Drugs) Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Oncology (Anti-cancer Drugs) Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli lilly
  32. 8.6.1 Eli lilly Company Information
  33. 8.6.2 Eli lilly Business Overview
  34. 8.6.3 Eli lilly Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli lilly Oncology (Anti-cancer Drugs) Product Portfolio
  36. 8.6.5 Eli lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Oncology (Anti-cancer Drugs) Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Oncology (Anti-cancer Drugs) Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Oncology (Anti-cancer Drugs) Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 Celgene
  56. 8.10.1 Celgene Company Information
  57. 8.10.2 Celgene Business Overview
  58. 8.10.3 Celgene Oncology (Anti-cancer Drugs) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Celgene Oncology (Anti-cancer Drugs) Product Portfolio
  60. 8.10.5 Celgene Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oncology (Anti-cancer Drugs) Value Chain Analysis
  2. 9.1.1 Oncology (Anti-cancer Drugs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oncology (Anti-cancer Drugs) Sales Mode & Process
  6. 9.2 Oncology (Anti-cancer Drugs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oncology (Anti-cancer Drugs) Distributors
  9. 9.2.3 Oncology (Anti-cancer Drugs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst